Sumitomo Mitsui Trust Group
DNA icon

Sumitomo Mitsui Trust Group’s Ginkgo Bioworks DNA Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-63,550
Closed -$850K – 1064
2024
Q2 		$850K Sell
63,550
-1,333,076
-95% -$39.8M ﹤0.01% 917
2024
Q1 		$64.8M Sell
1,396,626
-59,347
-4% -$3.07M 0.04% 420
2023
Q4 		$98.4M Sell
1,455,973
-12,681
-0.9% -$776K 0.07% 289
2023
Q3 		$106M Buy
1,468,654
+198,965
+16% +$15.9M 0.09% 241
2023
Q2 		$94.5M Buy
1,269,689
+204,774
+19% +$12.1M 0.07% 293
2023
Q1 		$56.7M Buy
1,064,915
+127,057
+14% +$8.05M 0.04% 456
2022
Q4 		$63.4M Buy
937,858
+163,309
+21% +$15M 0.05% 428
2022
Q3 		$96.7M Buy
774,549
+228,095
+42% +$27.2M 0.08% 296
2022
Q2 		$52M Buy
+546,454
New +$66.6M 0.04% 494
2022
Q1 		– Sell
-282,675
Closed -$94M – 1192
2021
Q4 		$94M Buy
282,675
+168,858
+148% +$80.2M 0.06% 360
2021
Q3 		$52.8M Buy
+113,817
New +$55.4M 0.03% 534

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sumitomo Mitsui Trust Group's DNA Position: Q3 2024 in Review

Sumitomo Mitsui Trust Group sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 63,550 shares — an estimated $850K sold.

Sumitomo Mitsui Trust Group first reported a position in DNA in Q3 2021 and held it in 11 quarters. The position peaked at $106M in Q3 2023. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Sumitomo Mitsui Trust Group reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Sumitomo Mitsui Trust Group sold 63,550 Ginkgo Bioworks shares in Q3 2024, an estimated $850K.
  • Sumitomo Mitsui Trust Group first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 11 quarters.
  • Sumitomo Mitsui Trust Group's Ginkgo Bioworks position peaked at $106M in Q3 2023.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q3 2024, filed 5 Nov 2024.